MARKET

GALT

GALT

Galectin Therapeutics Inc
NASDAQ
1.540
-0.030
-1.91%
After Hours: 1.590 +0.05 +3.25% 17:56 06/05 EDT
OPEN
1.510
PREV CLOSE
1.570
HIGH
1.590
LOW
1.510
VOLUME
62.95K
TURNOVER
0
52 WEEK HIGH
2.570
52 WEEK LOW
1.020
MARKET CAP
91.76M
P/E (TTM)
-2.2607
1D
5D
1M
3M
1Y
5Y
Galectin Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 4d ago
Galectin Therapeutics Rides Roller-Coaster Of Volatility
Seeking Alpha · 05/27 08:01
Galectin Therapeutics Inc: [Cover]SEC-generated letter
Press release · 05/22 18:05
Galectin Therapeutics Inc: Correspondence
Press release · 05/22 18:05
HC Wainwright & Co. Reiterates Galectin Therapeutics (GALT) Buy Recommendation
NASDAQ · 05/17 20:13
Analysts’ Top Healthcare Picks: Galectin Therapeutics (GALT), Cabaletta Bio (CABA)
TipRanks · 05/17 10:30
Galectin Therapeutics GAAP EPS of -$0.19
Seeking Alpha · 05/15 13:25
Galectin Therapeutics Q1 EPS $(0.19) Beats $(0.21) Estimate; The Company Had $17.8 Million Of Cash And Cash Equivalents, And Expects That It Will Require More Cash To Fund Operations After December 31, 2024
Benzinga · 05/15 12:18
More
About GALT
Galectin Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin, for the prevention of esophageal varices.

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.